|
US5700913A
(en)
|
1982-12-15 |
1997-12-23 |
Ajinomoto Co., Inc. |
Unglycosylated human interleukin-2 polypeptides
|
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
IL80678A
(en)
|
1985-11-19 |
1999-05-09 |
Schering Biotech Corp |
Human interleukin-4
|
|
US6028186A
(en)
|
1991-06-10 |
2000-02-22 |
Nexstar Pharmaceuticals, Inc. |
High affinity nucleic acid ligands of cytokines
|
|
US7008624B1
(en)
|
1995-02-22 |
2006-03-07 |
Immunex Corporation |
Antagonists of interleukin-15
|
|
US5795966A
(en)
|
1995-02-22 |
1998-08-18 |
Immunex Corp |
Antagonists of interleukin-15
|
|
US6037149A
(en)
|
1995-08-24 |
2000-03-14 |
Magainin Pharmaceuticals Inc. |
DNA encoding human asthma associated factor 1
|
|
IL130238A0
(en)
|
1999-06-01 |
2000-06-01 |
Peptor Ltd |
Conformationally constrained backbone cyclized interleukin-6 antagonists
|
|
CA2253942A1
(en)
|
1996-05-10 |
1997-11-20 |
Biogen, Inc. |
Common gamma chain blocking agents
|
|
US6127387A
(en)
|
1996-12-10 |
2000-10-03 |
Thomas Jefferson University |
Use of CD4-binding small molecules to inhibit immune responses
|
|
CN1269805A
(zh)
*
|
1997-07-14 |
2000-10-11 |
博尔德生物技术公司 |
生长激素和相关蛋白的衍生物
|
|
US7189400B2
(en)
|
1998-03-17 |
2007-03-13 |
Genetics Institute, Llc |
Methods of treatment with antagonists of MU-1
|
|
US7198789B2
(en)
|
1998-03-17 |
2007-04-03 |
Genetics Institute, Llc |
Methods and compositions for modulating interleukin-21 receptor activity
|
|
US6861227B2
(en)
|
1998-03-19 |
2005-03-01 |
Human Genome Sciences, Inc. |
Antibodies to cytokine receptor common gamma chain like
|
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
|
EP0972780A1
(en)
*
|
1998-05-18 |
2000-01-19 |
Applied Research Systems ARS Holding N.V. |
Il-6 antagonist peptides
|
|
US6307024B1
(en)
|
1999-03-09 |
2001-10-23 |
Zymogenetics, Inc. |
Cytokine zalpha11 Ligand
|
|
US7192713B1
(en)
|
1999-05-18 |
2007-03-20 |
President And Fellows Of Harvard College |
Stabilized compounds having secondary structure motifs
|
|
AU2001261585B2
(en)
|
2000-05-12 |
2006-08-31 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for achieving immune suppression
|
|
DE60138222D1
(de)
*
|
2000-09-14 |
2009-05-14 |
Beth Israel Hospital |
Modulierung von il-2 und il-15 vermittelten t zellantworten
|
|
MXPA03003407A
(es)
*
|
2000-10-18 |
2004-05-04 |
Immunex Corp |
Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.
|
|
US20040126900A1
(en)
|
2001-04-13 |
2004-07-01 |
Barry Stephen E |
High affinity peptide- containing nanoparticles
|
|
CA2452372A1
(en)
|
2001-07-06 |
2003-01-16 |
Sucampo Ag |
Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
|
|
CA2465268A1
(en)
|
2001-10-24 |
2003-05-01 |
National Jewish Medical And Research Center |
Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto
|
|
MXPA04004167A
(es)
*
|
2001-11-05 |
2004-07-08 |
Zymogenetics Inc |
Antagonistas de interleucina-21.
|
|
ES2382800T3
(es)
|
2002-01-18 |
2012-06-13 |
Zymogenetics, Inc. |
Multímeros Zcytor17 receptores de citocinas
|
|
US20050063947A1
(en)
|
2002-03-27 |
2005-03-24 |
Patrick Hwu |
Method for treating cancer in humans
|
|
WO2003087320A2
(en)
*
|
2002-04-09 |
2003-10-23 |
Beth Israel Deaconess Medical Center, Inc. |
Antagonists of il-21 and modulation of il-21-mediated t cell responses
|
|
JP2005525404A
(ja)
|
2002-05-01 |
2005-08-25 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｈｉｖ感染およびａｉｄｓを処置するためにサイトカインアンタゴニストを使用する方法
|
|
DK1531850T3
(da)
*
|
2002-06-07 |
2012-06-04 |
Zymogenetics Inc |
Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
|
|
WO2004002500A1
(en)
|
2002-06-28 |
2004-01-08 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
|
|
AU2003251633A1
(en)
|
2002-07-01 |
2004-01-19 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
Il-21 as a regulator of immunoglobin production
|
|
CN1688340A
(zh)
|
2002-07-15 |
2005-10-26 |
韦思公司 |
调节t辅助(th)细胞发育和功能的方法和组合物
|
|
US20060236411A1
(en)
*
|
2002-10-14 |
2006-10-19 |
Ingeborg Dreher |
Antagonists il-15
|
|
EP1444989A1
(en)
|
2003-02-07 |
2004-08-11 |
Giorgio Dr. Stassi |
Sensitizing cells for apoptosis by selectively blocking cytokines
|
|
AU2004224277A1
(en)
|
2003-03-21 |
2004-10-07 |
Wyeth |
Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
|
|
EP1622568B1
(en)
|
2003-05-14 |
2010-07-07 |
Bayer Pharmaceuticals Corporation |
Interleukin-9 antagonist muteins and their pharmacological methods of use
|
|
CA2529520A1
(en)
|
2003-06-19 |
2004-12-29 |
Centocor, Inc. |
Interleukin-21 analogs
|
|
DE602004031681D1
(de)
|
2003-07-21 |
2011-04-14 |
Transgene Sa |
Multifunktionelle Cytokine
|
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US7785580B2
(en)
|
2003-08-29 |
2010-08-31 |
Aerovance, Inc. |
Modified IL-4 mutein receptor antagonists
|
|
JP2007506789A
(ja)
|
2003-09-25 |
2007-03-22 |
ザイモジェネティクス， インコーポレイテッド |
Ｉｌ−２１を用いた自己免疫疾患の治療方法
|
|
US20060228331A1
(en)
|
2003-10-10 |
2006-10-12 |
Novo Nordisk A/S |
IL-21 Derivatives and variants
|
|
EP1708737A2
(en)
|
2004-01-15 |
2006-10-11 |
Novo Nordisk A/S |
Use of interleukin-21 for the treatment of autoimmune diseases and allograft rejection
|
|
ES2395087T3
(es)
|
2004-05-05 |
2013-02-08 |
Valorisation-Recherche, Société en Commandite |
Antagonistas del receptor de interleuquina-1, composiciones y métodos de tratamiento
|
|
US20060024268A1
(en)
|
2004-05-19 |
2006-02-02 |
Wyeth |
Modulation of immunoglobulin production and atopic disorders
|
|
CA2574848A1
(en)
|
2004-08-05 |
2006-12-21 |
Wyeth |
Antagonizing interleukin-21 receptor activity
|
|
CU23472A1
(es)
*
|
2004-09-17 |
2009-12-17 |
Ct Ingenieria Genetica Biotech |
Péptido antagonista de la interleucina-15
|
|
WO2006105538A2
(en)
|
2005-03-31 |
2006-10-05 |
Centocor, Inc. |
Methods and compositions for treating il-21 related pathologies
|
|
GT200600148A
(es)
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
|
MX2007012887A
(es)
|
2005-04-18 |
2007-12-10 |
Novo Nordisk As |
Variantes il-21.
|
|
PL1899364T5
(pl)
|
2005-05-17 |
2024-12-09 |
University Of Connecticut |
Kompozycje i sposoby immunomodulacji w organizmie
|
|
EP1940734A2
(en)
*
|
2005-08-10 |
2008-07-09 |
Northwestern University |
Composite particles
|
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
EP2805971A1
(en)
|
2005-11-28 |
2014-11-26 |
ZymoGenetics, Inc. |
IL-21 antagonists
|
|
WO2008031064A1
(en)
|
2006-09-07 |
2008-03-13 |
University Of South Florida |
Hyd1 peptides as anti-cancer agents
|
|
WO2008049920A2
(en)
|
2006-10-26 |
2008-05-02 |
Novo Nordisk A/S |
Il-21 variants
|
|
WO2008074863A1
(en)
|
2006-12-21 |
2008-06-26 |
Novo Nordisk A/S |
Interleukin-21 variants with altered binding to the il-21 receptor
|
|
US7910123B2
(en)
|
2007-09-05 |
2011-03-22 |
Warsaw Orthopedic |
Methods of treating a trauma or disorder of the knee joint by local administration and sustained-delivery of a biological agent
|
|
WO2009100035A2
(en)
|
2008-02-01 |
2009-08-13 |
Wyeth |
Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
|
|
WO2009108341A1
(en)
|
2008-02-28 |
2009-09-03 |
Argos Therapeutics, Inc. |
Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
|
|
WO2009132821A1
(en)
|
2008-04-28 |
2009-11-05 |
Giuliani International Limited |
Interleukin (il-21) binding proteins and methods of making and using same
|
|
EP2303353B1
(en)
*
|
2008-06-12 |
2018-01-10 |
Ramot at Tel-Aviv University Ltd. |
Drug-eluting medical devices
|
|
US20110144306A1
(en)
|
2008-07-23 |
2011-06-16 |
President And Fellows Of Harvard College |
Ligation of stapled polypeptides
|
|
US20100075329A1
(en)
|
2008-09-23 |
2010-03-25 |
O'toole Margot |
Methods for predicting production of activating signals by cross-linked binding proteins
|
|
CA2743394C
(en)
|
2008-11-17 |
2018-01-02 |
Koebenhavns Universitet |
Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
|
|
WO2010076339A1
(en)
|
2009-01-05 |
2010-07-08 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
|
|
TW201613969A
(en)
|
2009-03-05 |
2016-04-16 |
Abbvie Inc |
IL-17 binding proteins
|
|
WO2010103038A1
(en)
|
2009-03-11 |
2010-09-16 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
|
GB0908613D0
(en)
|
2009-05-20 |
2009-06-24 |
Immunocore Ltd |
T Cell Reseptors
|
|
BR112012000867A2
(pt)
|
2009-07-13 |
2019-09-24 |
Harvard College |
"polipeptídeos bifuncional costurado e uso do mesmo"
|
|
EP2511294B1
(en)
|
2009-12-11 |
2014-02-26 |
Proyecto de Biomedicina Cima, S.L. |
Conjugates and compositions for immunotherapy and anti-tumoral treatment
|
|
JP5835741B2
(ja)
*
|
2010-02-26 |
2015-12-24 |
国立大学法人 長崎大学 |
抗原または薬物送達複合体
|
|
US9782454B2
(en)
|
2010-04-22 |
2017-10-10 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
|
US8822642B2
(en)
|
2010-06-09 |
2014-09-02 |
Zymogenetics, Inc. |
Dimeric fusion proteins and related compositions and methods
|
|
US9084761B2
(en)
*
|
2010-07-09 |
2015-07-21 |
The Regents Of The University Of California |
Use of interleukin-15 to treat cardiovascular diseases
|
|
WO2012012531A2
(en)
|
2010-07-20 |
2012-01-26 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods featuring il-6 and il-21 antagonists
|
|
ES2778053T3
(es)
|
2011-01-18 |
2020-08-07 |
Bioniz Llc |
Composiciones para modular la actividad de la citocina gamma-c
|
|
WO2015089217A2
(en)
|
2013-12-10 |
2015-06-18 |
Bionz, Llc |
Methods of developing selective peptide antagonists
|
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
|
US9670672B2
(en)
|
2014-12-03 |
2017-06-06 |
Aleksandar Stevanov |
Roof panel system
|
|
JP6800219B2
(ja)
|
2015-09-16 |
2020-12-16 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
特異的なインターロイキン−１５（ｉｌ−１５）アンタゴニストポリペプチド並びに炎症疾患及び自己免疫疾患の処置のためのその使用
|
|
US20170104927A1
(en)
|
2015-10-07 |
2017-04-13 |
Little Star Media, Inc. |
Systems, methods and software programs for 360 degree video distribution platforms
|
|
EP3359556B1
(en)
|
2015-10-09 |
2021-05-26 |
Bioniz, LLC |
Modulating gamma - c -cytokine activity
|
|
SG11201903882VA
(en)
|
2016-11-08 |
2019-05-30 |
Delinia Inc |
Il-2 variants for the treatment of autoimmune diseases
|
|
KR20240142577A
(ko)
|
2017-04-07 |
2024-09-30 |
바이오니즈 테라퓨틱스, 아이엔씨. |
감마-c-사이토카인 활성의 안정한 조절자
|
|
JP2022530677A
(ja)
|
2019-05-03 |
2022-06-30 |
バイオニズ リミテッド ライアビリティー カンパニー |
脱毛症および脱毛症関連障害の治療ための、γｃサイトカインのシグナル伝達の効果の調節
|